National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:Allogeneic Melanoma Cell-Loaded Dendritic Cell Vaccine
US brand name:Uvidem
Code name:IDD-3



Previous:autologous anti-gp100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes, autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, autologous anti-PSMA gene-modified T-cells, autologous dendritic cell-adenovirus CCL21 vaccine, autologous dendritic cell-adenovirus p53 vaccine
Next:autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine, autologous dendritic cell-tumor fusion vaccine, autologous dinitrophenyl-modified ovarian cancer vaccine, autologous EBV-CTL CD19CAR zeta, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov